Russell Investments Group’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.7M | Buy |
301,566
+127,537
| +73% | +$9.16M | 0.02% | 637 |
|
|
2026
Q1 | $11.5M | Buy |
174,029
+36,339
| +26% | +$2.31M | 0.01% | 855 |
|
|
2025
Q4 | $8.75M | Buy |
137,690
+17,800
| +15% | +$1.11M | 0.01% | 998 |
|
|
2025
Q3 | $6.59M | Sell |
119,890
-31,951
| -21% | -$1.32M | 0.01% | 1145 |
|
|
2025
Q2 | $5.02M | Buy |
151,841
+102,403
| +207% | +$3.56M | 0.01% | 1219 |
|
|
2025
Q1 | $1.99M | Sell |
49,438
-43,543
| -47% | -$2M | ﹤0.01% | 1701 |
|
|
2024
Q4 | $4.37M | Sell |
92,981
-62,699
| -40% | -$3.26M | 0.01% | 1236 |
|
|
2024
Q3 | $8.22M | Sell |
155,680
-2,562
| -2% | -$143K | 0.01% | 923 |
|
|
2024
Q2 | $8.57M | Sell |
158,242
-87,399
| -36% | -$5.28M | 0.01% | 889 |
|
|
2024
Q1 | $17.2M | Sell |
245,641
-6,481
| -3% | -$501K | 0.03% | 606 |
|
|
2023
Q4 | $21M | Sell |
252,122
-37,435
| -13% | -$1.36M | 0.04% | 493 |
|
|
2023
Q3 | $8.53M | Buy |
289,557
+50,966
| +21% | +$1.7M | 0.02% | 827 |
|
|
2023
Q2 | $7.78M | Buy |
238,591
+18,866
| +9% | +$698K | 0.02% | 894 |
|
|
2023
Q1 | $7.73M | Sell |
219,725
-12,906
| -6% | -$527K | 0.02% | 889 |
|
|
2022
Q4 | $10.7M | Sell |
232,631
-131,092
| -36% | -$5.64M | 0.02% | 736 |
|
|
2022
Q3 | $17.6M | Buy |
363,723
+39,285
| +12% | +$1.89M | 0.04% | 526 |
|
|
2022
Q2 | $12.7M | Buy |
324,438
+118,403
| +57% | +$4.77M | 0.03% | 676 |
|
|
2022
Q1 | $7.58M | Buy |
206,035
+6,551
| +3% | +$233K | 0.01% | 941 |
|
|
2021
Q4 | $9.09M | Buy |
199,484
+6,813
| +4% | +$263K | 0.01% | 944 |
|
|
2021
Q3 | $6.88M | Buy |
192,671
+23,211
| +14% | +$683K | 0.01% | 1073 |
|
|
2021
Q2 | $3.35M | Buy |
169,460
+76,723
| +83% | +$1.8M | 0.01% | 1602 |
|
|
2021
Q1 | $2.15M | Buy |
92,737
+17,057
| +23% | +$364K | ﹤0.01% | 1837 |
|
|
2020
Q4 | $1.57M | Sell |
75,680
-38,007
| -33% | -$695K | ﹤0.01% | 1883 |
|
|
2020
Q3 | $2.46M | Buy |
113,687
+48,519
| +74% | +$1.13M | 0.01% | 1551 |
|
|
2020
Q2 | $1.53M | Sell |
65,168
-30,810
| -32% | -$578K | ﹤0.01% | 1795 |
|
|
2020
Q1 | $1.13M | Buy |
95,978
+90,268
| +1,581% | +$1.15M | ﹤0.01% | 1780 |
|
|
2019
Q4 | $59K | Buy |
+5,710
| New | +$58.7K | ﹤0.01% | 2974 |
|
|
2018
Q3 | – | Sell |
-2,000
| Closed | -$17K | – | 2961 |
|
|
2018
Q2 | $17K | Buy |
+2,000
| New | +$16.6K | ﹤0.01% | 2877 |
|
|
2017
Q4 | – | Sell |
-190,026
| Closed | -$2.75M | – | 2961 |
|
|
2017
Q3 | $2.75M | Sell |
190,026
-69,807
| -27% | -$954K | ﹤0.01% | 1595 |
|
|
2017
Q2 | $3.14M | Buy |
259,833
+93,504
| +56% | +$1.3M | 0.01% | 1479 |
|
|
2017
Q1 | $2.14M | Buy |
+166,329
| New | +$1.94M | ﹤0.01% | 1725 |
|
Other funds holding CYTK
ACA
Russell Investments Group's CYTK Position: Q2 2026 in Review
Russell Investments Group increased its Cytokinetics (CYTK) stake by 73% in Q2 2026, buying an estimated $9.16M and bringing the position to 301,566 shares worth $25.7M. The position accounts for 0.02% of the portfolio, ranked #637.
Russell Investments Group first reported a position in CYTK in Q1 2017 and has held it in 31 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Russell Investments Group held 301,566 shares of Cytokinetics worth $25.7M as of Q2 2026.
- Russell Investments Group bought 127,537 Cytokinetics shares in Q2 2026, an estimated $9.16M.
- Cytokinetics made up 0.02% of Russell Investments Group's portfolio in Q2 2026, its #637 holding.
- Russell Investments Group first reported a position in Cytokinetics in Q1 2017 and has held it in 31 quarters since.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.